Table 4:
Overall | Incident ILD Cases | Controls | P value | ||
---|---|---|---|---|---|
N | 58 | 22 | 36 | ||
Age, median (IQR) | 65 (60, 69) | 65 (64, 70) | 65 (59.5, 69) | 0.77 | |
Male (%) | 54 (93) | 20 (91) | 34 (94) | 0.61 | |
Race (%) | White or Caucasian | 43 (74) | 16 (73) | 27 (75) | 0.52 |
Black or African American | 10 (17) | 5 (23) | 5 (14) | ||
Other | 5 (9) | 1 (5) | 4 (11) | ||
Ethnicity (%) | Hispanic or Latino | 3 (5) | 1 (5) | 2 (6) | 0.84 |
Not Hispanic or Latino | 51 (88) | 20 (91) | 31 (86) | ||
Missing | 4 (7) | 1 (5) | 3 (8) | ||
BMI, median (IQR) | 28.8 (25.0, 31.1) | 29.1 (24.6, 31.1) | 28.7 (25.7, 31.0) | 0.76 | |
Smoking history (%) | Never | 11 (19) | 3 (14) | 8 (22) | 0.14 |
Former | 11 (19) | 7 (32) | 4 (11) | ||
Current | 36 (62) | 12 (55) | 24 (67) | ||
Hypertension (%) | 6 (10) | 3 (8) | 3 (14) | 0.52 | |
Cardiac disease (%) | 1 (2) | 1 (3) | 0 (0) | 0.43 | |
Diabetes mellitus (%) | 8 (14) | 3 (8) | 5 (23) | 0.12 | |
COPD or asthma (%) | 2 (3) | 1 (3) | 1 (5) | 0.72 | |
RA disease duration, years, median (IQR) | 10.5 (1.8, 17.4) | 8.0 (1.8, 15.3) | 10.8 (3.2, 19.0) | 0.30 | |
DAS28, median (IQR) | 3.0 (2.3, 4.2) | 2.9 (2.4, 3.8) | 3.2 (2.2, 4.5) | 0.67 | |
MDHAQ, median (IQR) | 0.7 (0.4, 1.2) | 0.8 (0.4, 1.1) | 0.7 (0.4, 1.2) | 0.76 | |
Prednisone use (%) | 27 (47) | 11 (50) | 16 (44) | 0.68 | |
Methotrexate use (%) | 33 (57) | 15 (68) | 18 (50) | 0.17 | |
Anti-TNF use (%) | 20 (34) | 8 (36) | 12 (33) | 0.81 |
Abbreviations: RA-ILD = rheumatoid arthritis-associated interstitial lung disease; IQR = interquartile range; BMI = body mass index; COPD = chronic obstructive pulmonary disease; RA = rheumatoid arthritis; DAS28 = Disease Activity Score in 28 Joints; MDHAQ = Multidimensional Health Assessment Questionnaire; TNF = tumor necrosis factor.